ENOB

Keysight Introduces Hardware-Accelerated Oscilloscope with Automated Analysis Tools

Retrieved on: 
Tuesday, September 12, 2023
Technology, Engineering, Hardware, Manufacturing, NYSE, MXR, ENOB, Multimedia, Anomaly, ASIC, Television

Keysight Technologies, Inc. (NYSE: KEYS), announces the expansion of its industry-leading portfolio of Infiniium oscilloscopes with the new, hardware-accelerated Infiniium MXR B-Series , offering automated analysis tools that enable engineers to find anomalies quickly and shorten time to market.

Key Points: 
  • Keysight Technologies, Inc. (NYSE: KEYS), announces the expansion of its industry-leading portfolio of Infiniium oscilloscopes with the new, hardware-accelerated Infiniium MXR B-Series , offering automated analysis tools that enable engineers to find anomalies quickly and shorten time to market.
  • View the full release here: https://www.businesswire.com/news/home/20230912211991/en/
    The new hardware-accelerated Keysight Infiniium MXR B-Series oscilloscopes offers automated analysis tools that enable engineers to find anomalies quickly and shorten time to market.
  • Superior scope signal integrity combined with built-in, automated analysis tools enable engineers to reduce test and debug times and get to market faster.
  • Keysight’s Infiniium MXR B-Series meets these needs by giving engineers built-in, automated debug tools such as zone triggering, fault detection, real-time spectrum analysis (RTSA), and a 50 MHz waveform generator.

Edelson Lechtzin LLP Reminds Enochian Biosciences, Inc. Investors of the Impending Lead Plaintiff Deadline

Retrieved on: 
Thursday, September 22, 2022
Complaint, Felony, Central District, Coronavirus, U.S. Department of Justice Office of Legislative Affairs, Douglas v. U.S. District Court ex rel Talk America, Company, News, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, ENOB, LLP, Cancer, Lists of schools in England, Hepatitis B virus, HIV, NASDAQ, China Biologic Products, GLOBE, District court, Hindenburg Research, Online gambling, Pharmaceutical industry, Enochian

Investors who purchased Enochian during the Class Period have until September 26, 2022 to select counsel and move for appointment as a lead plaintiff.

Key Points: 
  • Investors who purchased Enochian during the Class Period have until September 26, 2022 to select counsel and move for appointment as a lead plaintiff.
  • The lead plaintiff acts as a representative for other class members in directing the litigation.
  • If you continue to hold Enochian shares and wish to discuss your legal options, please contact Edelson Lechtzin LLP, toll free at 1-844-696-7492, or by email at [email protected].
  • This news caused the price of Enochian stock to plummet an additional 28%, or $1.495 a share, to close at $3.77.

Enochian Biosciences Inc. Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Enochian Biosciences Inc. (ENOB)

Retrieved on: 
Friday, August 12, 2022
Steps, HIV, Technology, Hindenburg Research, Securities Exchange Act of 1934, Cancer, Coronavirus, Theft, U.S. Department of Justice Office of Legislative Affairs, Felony, Company, U.S. Department of Defense Strategy for Operating in Cyberspace, Fraud, Hindenburg, NASDAQ, News, Science, Hepatitis B virus, China Biologic Products, ENOB, Justice, Complaint, Person, Crime, Enochian

If you would like more information about Enochian Biosciences Inc.'s misconduct, click here .

Key Points: 
  • If you would like more information about Enochian Biosciences Inc.'s misconduct, click here .
  • On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.
  • On this news, the price of Enochian's stock fell almost 37%, to close at $3.70 per share on May 25, 2022.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Enochian Biosciences Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Enochian Biosciences Inc. (ENOB)

Retrieved on: 
Monday, August 1, 2022
Class Action Lawsuit, Professional Services, Legal, Steps, Crime, Felony, Hindenburg, Theft, Hepatitis B virus, Person, China Biologic Products, Securities Exchange Act of 1934, HIV, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, Fraud, Cancer, News, U.S. Department of Defense Strategy for Operating in Cyberspace, Technology, Company, Science, Justice, Hindenburg Research, Complaint, Coronavirus, ENOB, Enochian

The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Enochian Biosciences Inc. (NASDAQ: ENOB) securities between September 24, 2020 and May 31, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Enochian Biosciences Inc. (NASDAQ: ENOB) securities between September 24, 2020 and May 31, 2022, for violations of the Securities Exchange Act of 1934.
  • If you would like more information about Enochian Biosciences Inc.'s misconduct, click here .
  • On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Enochian Biosciences Inc. (ENOB)

Retrieved on: 
Thursday, July 28, 2022
Legal, Professional Services, Steps, Crime, Felony, Hindenburg, Theft, Hepatitis B virus, Person, China Biologic Products, Securities Exchange Act of 1934, HIV, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, Fraud, Cancer, News, U.S. Department of Defense Strategy for Operating in Cyberspace, Technology, Company, Science, Justice, Hindenburg Research, Complaint, Coronavirus, ENOB, Enochian

The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Enochian Biosciences Inc. (NASDAQ: ENOB) securities between September 24, 2020 and May 31, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Enochian Biosciences Inc. (NASDAQ: ENOB) securities between September 24, 2020 and May 31, 2022, for violations of the Securities Exchange Act of 1934.
  • If you would like more information about Enochian Biosciences Inc.'s misconduct, click here .
  • On May 25, 2022, the U.S. Department of Justice announced that Gumrukcu had been arrested and charged in a murder-for-hire conspiracy.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Enochian Biosciences (ENOB) Investors with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on: 
Tuesday, June 28, 2022
Fraud, Research, Hindenburg Research, HIV, Commerce, District, Steve Berman (lawyer), Person, ENOB, SEC, Hindenburg, Medicine, FBI, News, Program, Pharmaceutical industry, Enochian

Attorneys office, the murder of Gregory Davis was potentially motivated by Davis threat to inform the FBI that Gumrukcu and his brother were defrauding Davis in a multi-million-dollar oil deal.

Key Points: 
  • Attorneys office, the murder of Gregory Davis was potentially motivated by Davis threat to inform the FBI that Gumrukcu and his brother were defrauding Davis in a multi-million-dollar oil deal.
  • If you invested in Enochian and suffered substantial losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Whistleblowers: Persons with non-public information regarding Enochian should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Enochian Biosciences (ENOB) Investors With Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on: 
Tuesday, June 14, 2022
Hindenburg Research, Fraud, Commerce, Person, FBI, Research, Program, NASDAQ, News, SEC, Hindenburg, HIV, District, ENOB, Steve Berman (lawyer), Medicine, SAN, GLOBE, Pharmaceutical industry, Enochian

SAN FRANCISCO, June 14, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Enochian Biosciences, Inc. (NASDAQ: ENOB) investors with significant losses to submit your transactions now .

Key Points: 
  • SAN FRANCISCO, June 14, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Enochian Biosciences, Inc. (NASDAQ: ENOB) investors with significant losses to submit your transactions now .
  • The firm is investigating possible securities law violations.
  • If you invested in Enochian and suffered substantial losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Enochian Biosciences (ENOB) Investors with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on: 
Wednesday, June 8, 2022
Program, Research, Hindenburg, News, Steve Berman (lawyer), Fraud, Commerce, GLOBE, ENOB, Person, Hindenburg Research, NASDAQ, SAN, SEC, District, FBI, HIV, Medicine, Pharmaceutical industry, Enochian

SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Enochian Biosciences, Inc. (NASDAQ: ENOB) investors with significant losses to submit your transactions now .

Key Points: 
  • SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Enochian Biosciences, Inc. (NASDAQ: ENOB) investors with significant losses to submit your transactions now .
  • The firm is investigating possible securities law violations.
  • If you invested in Enochian and suffered substantial losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Enochian Biosciences (ENOB) Investors With Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations

Retrieved on: 
Thursday, June 2, 2022
Program, Research, Hindenburg, News, Steve Berman (lawyer), Fraud, Commerce, GLOBE, ENOB, Person, Hindenburg Research, NASDAQ, SAN, SEC, District, FBI, HIV, Medicine, Pharmaceutical industry, Enochian

SAN FRANCISCO, June 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Enochian Biosciences, Inc. (NASDAQ: ENOB) investors with significant losses to submit your transactions now .

Key Points: 
  • SAN FRANCISCO, June 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Enochian Biosciences, Inc. (NASDAQ: ENOB) investors with significant losses to submit your transactions now .
  • The firm is investigating possible securities law violations.
  • If you invested in Enochian and suffered substantial losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

Leading the Future of T&M Industry

Retrieved on: 
Tuesday, November 23, 2021
ENOB, MSO, Computer, Technology, Industry, Noise, ASEAN, Transport, Student, Leadership, Solution, History, Quantum, Software, Research, Communication, Cloud computing, Region, Knowledge, Efficiency, Tektronix, Engineering, Multimedia, EE Times, Television, Video game console, Online shopping, Renewable energy

In line with this, Tektronix has been developing solutions that stay ahead of those speeds to test the future of computing.

Key Points: 
  • In line with this, Tektronix has been developing solutions that stay ahead of those speeds to test the future of computing.
  • That means not just advancing today's 5G mobile networks but investing in the future of 6G as well.
  • Tektronix's 6 Series B MSO delivers industry leading signal fidelity, contributing less than 51.1V of noise at 1mV/div and 1GHz, and less than 1.39mV of noise at 50mV/div and 10GHz.
  • We are honored to be a winner and look forward to continuing contribute to the industry and with EE Times for the advancement of our future," says Tan.